Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of HS-20004 in Healthy Chinese Subjects
NCT02746302Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2012
- Primary completion
- Jan 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing HS-20004 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Dec 2012; status: completed.
02
Drugs
noiiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02746302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02746302.